Page last updated: 2024-11-05

2-hydroxyemodin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID11818503
MeSH IDM0150396

Synonyms (23)

Synonym
anthraquinone, 6-methyl-1,2,3,8-tetrahydroxy-
2-hydroxyemodin
brn 2008369
6-methyl-1,2,3,8-tetrahydroxyanthraquinone
1,2,6,8-tetrahydroxy-3-methyl-9,10-anthracenedione
9,10-anthracenedione, 1,2,6,8-tetrahydroxy-3-methyl-
alaternin (quinone)
ccris 5312
641-90-7
unii-87c66se4cp
4-08-00-03689 (beilstein handbook reference)
87c66se4cp ,
hydroxyemodin, 2-
1,2,6,8-tetrahydroxy-3-methylanthraquinone
1,2,6,8-tetrahydroxy-3-methylanthracene-9,10-dione
9,10-anthracenedione, 1,2,6,8-tetrahydroxy-3-methyl-(9ci)
Q27269815
MS-24076
HY-N10322
CS-0379968
DTXSID901031679
AKOS040762810
1,2,6,8-tetrahydroxy-3-methyl anthraquinone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's2 (22.22)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]